Drawing for MEDUSA

USPTO serial 79153955

MEDUSA

Reviewed by CopyMark Law Group

Reg. 4920030Status 404
Filing date
Status date
Registration date
Mar 22, 2016
Examiner
VALLILLO, MELISSA C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MEDUSA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Chemical compounds for use in drug delivery platforms, namely, encapsulating protein, lipid micro and nanoparticles, with such particles featuring micro or nanovectors, and chemicals for use in the encapsulation of active chemical ingredients; all the aforementioned goods not for use in the agriculture/plant businessSECTION 71 - CANCELLED—
005Pharmaceutical preparations, namely, vaccines, antivirals, antibiotics, anti-inflammatory preparations, antibacterial preparations, antimicrobial preparations, antifungal preparations, dietary and nutritional supplements, all featuring a hydrogel comprised of protein, lipid micro and nanoparticles for use in encapsulation of active pharmaceutical, dietetic, fungicidal, bactericidal, virucidal and vaccine ingredients for subcutaneous, sustained release, delivery of a wide range of small molecules, peptides and protein drugs; all the aforementioned goods not for use in the agriculture/plant businessSECTION 71 - CANCELLED—
040Manufacture and processing of polymers for the controlled release of active ingredients or of a combination of active ingredients; production of chemical and pharmaceutical preparations for others; treatment of chemical and pharmaceutical substances for others, namely, encapsulation and transformation of chemical and pharmaceutical substances aimed at ensuring oral absorption, stabilization, solubilisation, anti-aggregation, extended and controlled release of pharmaceutical active principles or combination of active principles; all the aforementioned services not for use in the agriculture/plant businessSECTION 71 - CANCELLED—
042Research and development of pharmaceutical preparations and medicinal solutions; formulation and development of chemical and pharmaceutical products; development of chemical and pharmaceutical product formulations for incorporation in pharmaceutical preparations in order to improve efficiency, reduce toxicity and improve the delivery system to the patient; research and development in the medical, pharmaceutical and chemical fields; research and development in the field of galenic innovation; chemical and biochemical analyses; technical consultancy and advice in the field of chemical and pharmaceutical formulation; all the aforementioned services not for use in the agriculture/plant businessSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 26, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 26, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 31, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jul 12, 2023INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jul 11, 2023INPCINVALIDATION PROCESSED—
Jun 7, 2023INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 27, 2023NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 7, 2022C71TCANCELLED SECTION 71—
Mar 22, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 14, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 1, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 1, 2016DCPNCHANGE OF OWNER RECEIVED FROM IB—
Jun 27, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 27, 2016FIMPFINAL DISPOSITION PROCESSED—
Jun 22, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 22, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 5, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 5, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 4, 2016GPNXNOTIFICATION PROCESSED BY IB—
Dec 16, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 16, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 16, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 30, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 19, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 18, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 18, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 18, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 27, 2015GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 27, 2015GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 27, 2015CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 29, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 29, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 24, 2015ALIEASSIGNED TO LIE—
Apr 23, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 5, 2014RFNPREFUSAL PROCESSED BY IB—
Nov 14, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 14, 2014RFRRREFUSAL PROCESSED BY MPU—
Nov 13, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 12, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2014RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Nov 8, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 7, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 7, 2014RFWRNON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW—
Nov 7, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 6, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 5, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2014DOCKASSIGNED TO EXAMINER—
Nov 3, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 30, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance